Sign in with Google
Sign in with Facebook
Sign in with Apple
The Paris Stock Exchange shows a 0 .11% decline this Tuesday at midday , with the CAC 40 index standing at 8116 .19 points amid a backdrop of widespread caution . Investors are treading carefully ahead of the release of key US employment statistics , as the Paris market struggles to break out of the ...
Abivax: Negative Financial Results But Growth Potential for the Biotech Sector
Sanofi trails as CAC 40 rises
The French luxury giant LVMH released its results for the first nine months of the year on October 14, 2025. The group reports consolidated revenue of €58.09 billion, showing a decline of 4% based on published data. However, the third quarter marks a turning point: organic growth has returned to a positive 1%, driven by improvements in Asia excluding Japan and the strong performance of Sephora. Exchange rate effects remain a significant drag, impacting the July-September period by as much as 5%.
The Paris Stock Exchange is showing a strong rebound this Monday at mid-session, with the CAC 40 index up 1.06% to reach 8,154.13 points. At the start of a crucial week highlighted by the European Central Bank meeting on Thursday, investors are focusing on growth stocks. European markets are benefiting from renewed optimism despite ongoing uncertainties about monetary policy. Traders will closely monitor the upcoming US economic data this week, particularly the November employment figures, which were delayed due to the budget impasse.
The continued rise of the S&P 500 conceals an increasingly visible divide. Behind the stock market performance, the profits of large publicly traded companies now follow a significantly different trajectory from those of the American economy as a whole. This disparity raises questions about the strength of the ongoing cycle.
By midday on Friday, December 12th, the CAC 40 is consolidating its gains in the wake of Wall Street and the accommodative decision by the US Federal Reserve. The French benchmark index is up 0.58% at noon, benefiting from a widespread positive dynamic that places Paris at the forefront of European stock markets. The French market is showcasing remarkable vitality, with a broad bullish consensus driven by cyclical sectors and banking stocks.
The Paris Stock Exchange ended Thursday in positive territory, with the CAC 40 rising 0.79% to close at 8,086 points. This increase reflects a reassuring context in European markets, which are emerging as the continent's top performers following the Federal Reserve's decision to continue its monetary easing cycle. However, the session was not uniform, with notable sectoral divergences and some disappointments impacting certain leading stocks in the French benchmark index.
After a November marked by a steep correction followed by a swift rebound, the markets are entering the end of the year with strengthened positions and an overall favorable macroeconomic scenario.
The Paris market closed with a slight decline on Wednesday, December 10, 2025, with the CAC 40 slipping 0.37% amid anticipation ahead of the US Federal Reserve's decision. This session was characterized by pronounced sectorial divergences, where certain technology and industrial stocks significantly weighed on the benchmark index, while commodities and consumer sectors showed resilience.
The French biotech company, involved in the clinical development of Obefazimod for ulcerative colitis, has released its results for the nine months ended September 30, 2025. While revenue-generating activity remains minimal, the company has strengthened its financial structure thanks to a fundraising of nearly 600 million euros completed in July, ensuring its autonomy until the fourth quarter of 2027.
The Paris market saw a welcome rebound this Monday, December 15, at the close of trading, with the CAC 40 rising by 0.70% to 8,125 points. In a traditionally calm year-end context but packed with economic data this week, investors showed a degree of caution despite this uptick. The main index benefited from the dynamism of industrial stocks like Schneider Electric, while the pharmaceutical sector suffered due to Sanofi's setback. This session highlights the contrasts driving the Paris stock exchange as it approaches the final full week of 2025, balancing hopes of a year-end rally with caution over regulatory and monetary uncertainties.
